van Drongelen J, Ploemen IH, Pertijs J, Gooi JH, Sweep FC, Lotgering FK, Spaanderman ME, Smits P. Aging attenuates the vasodilator response to relaxin. Am J Physiol Heart Circ Physiol 300: H1609 -H1615, 2011. First published February 18, 2011 doi:10.1152/ajpheart.00360.2010.-Relaxin, an insulin-like growth factor peptide, increases endothelium-dependent vasodilation and vascular compliance and decreases myogenic reactivity. These vascular effects significantly contribute to the physiological circulatory adaptations in pregnancy, particularly in the mesentery and kidney. Aging predisposes to vascular maladaptation and gestational hypertensive disease. We hypothesized that mild aging reduces the vascular responses to relaxin. In 20 young (10 -12 wk) and 20 middle-aged (40 -46 wk) female Wistar Hannover rats, vascular responses to chronic exposure of relaxin vs. placebo (5 days) were quantified in isolated mesenteric arteries and kidney. Vascular responses were evaluated using pressure-perfusion myograph, wire myograph, and an isolated perfused rat kidney model. Rxfp1 (relaxin family peptide) gene expression was determined by quantitative polymerase chain reaction. In young rats, relaxin stimulated nitric oxide (NO)-dependent flow-mediated vasodilation (2.67-fold, from 48 Ϯ 9 to 18 Ϯ 4 l/min), reduced myogenic reactivity (from Ϫ1 Ϯ 2 to 7 Ϯ 3 m/10 mmHg), and decreased mesenteric sensitivity to (28%, from 1.39 Ϯ 0.08 to 1.78 Ϯ 0.10 M) but did not change compliance and renal perfusion flow (RPFF). In aged rats, relaxin did not affect any of the analyzed mesenteric or renal parameters. In aged compared with young placebo-treated rats, all mesenteric characteristics were comparable, while RPFF was lower (17%, from 6.9 Ϯ 0.2 to 5.7 Ϯ 0.1 ml·min Ϫ1 ·100 g Ϫ1 ) even though NO availability was comparable. Rxfp1 expression was not different among young and aged rats. Our findings suggest that moderate aging involves normal endothelial function but blunts the physiological endothelium-dependent and -independent vasodilator response to relaxin. relaxin-resistance; Wistar Hannover rats; mesenteric arteries; isolated perfused rat kidney; human recombinant relaxin RELAXIN, A MEMBER OF THE insulin-like growth factor superfamily, is an important factor in achieving vasodilation in pregnancy (8). In vivo studies suggest that relaxin-induced renal vascular relaxation is the consequence of an activated endothelial nitric oxide (NO) release and an attenuated response to angiotensin II in rats (9). Additionally, in vitro experiments in renal and mesenteric rat arteries have shown that relaxin decreases myogenic reactivity (26) and increases compliance (21). Relaxin infusion induces vasodilation comparable to that observed in pregnancy (4, 23, 29), whereas relaxin neutralizing antibodies completely diminish pregnancy-induced vascular vasodilation (25). These findings suggest that relaxin is involved in gestational vascular adaptation.
RELAXIN, A MEMBER OF THE insulin-like growth factor superfamily, is an important factor in achieving vasodilation in pregnancy (8) . In vivo studies suggest that relaxin-induced renal vascular relaxation is the consequence of an activated endothelial nitric oxide (NO) release and an attenuated response to angiotensin II in rats (9) . Additionally, in vitro experiments in renal and mesenteric rat arteries have shown that relaxin decreases myogenic reactivity (26) and increases compliance (21) . Relaxin infusion induces vasodilation comparable to that observed in pregnancy (4, 23, 29) , whereas relaxin neutralizing antibodies completely diminish pregnancy-induced vascular vasodilation (25) . These findings suggest that relaxin is involved in gestational vascular adaptation.
Moderate aging is an independent risk factor for gestational hypertensive disease, doubling the risk above a maternal age of 40 years (16) . It relates to reduced flow-mediated vasodilation (1) and increased sensitivity to phenylephrine in female rat mesenteric arteries (13) . It also reduces myogenic reactivity without affecting vascular compliance in mice (19) . Other studies report beneficial vascular effects of relaxin treatment in aged subjects (10, 35) . Attenuation of the pregnancy-induced increase in flow-mediated vasodilation, and reduction in phenylephrine sensitivity and myogenic reactivity, possibly induced by impaired response to relaxin, may be coupled to the development of gestational hypertensive disease (18, 32) .
We hypothesized that moderate aging (at the end of the reproductive lifespan) blunts the vascular responses to relaxin and subsequently induces relaxin resistance, defined as the inability to produce comparable vascular responses to relaxin exposure as observed in young subjects. For this reason, we studied the effect of chronic exposure to relaxin in young vs. moderately aged rats. The mesenteric and renal vascular beds are both important determinants of pregnancy-induced changes in peripheral resistance, increasing their perfusion by 65 and 40%, respectively (2, 5) . Therefore, we addressed our hypothesis by investigating the vascular responses to relaxin in isolated mesenteric arteries and the isolated perfused rat kidney (IPRK).
MATERIALS AND METHODS
Animals. The experimental protocol was approved by the Animal Experiments Committee of the Radboud University Nijmegen Medical Centre and was performed in accordance to the European guidelines on animal experiments. Forty female virgin Wistar Hannover rats (Harlan Netherlands, Horst, The Netherlands) were used in the experiments. Young rats (n ϭ 20, 10 -12 wk old) and aged rats (n ϭ 20, 40 -46 wk old) received standard rodent chow (ssniff R/M-H) and water ad libitum. We housed all rats in pairs in filter-top cages on a 12:12-h light-dark cycle. Rats were randomly assigned (independent from estrous stage) to treatment for 5 days with either placebo or recombinant human relaxin (both containing 5 mM sodium acetate, pH 5.0; Corthera, San Mateo, CA). Human recombinant relaxin induces vascular responses comparable to those exerted by rat relaxin (9, 25) . On day 0, an osmotic minipump (Alzet, model 2001; DURECT, Cupertino, CA) was placed subcutaneously under isoflurane anesthesia. The osmotic minipump delivered the study medication at a dose of 4 g/h during 5 days to achieve plasma relaxin concentrations normally present on day 11 of gestation in rats (9) . On day 5, the rats were anaesthetized with an intraperitoneal injection of pentobarbital (6 mg/100 g body wt; Apharmo, Arnhem, The Netherlands). Furosemide (1 mg/100 g body wt; Sigma-Aldrich Chemie, Zwijndrecht, The Netherlands) was also injected intraperitoneally to achieve maximal urethral distention for optimal catheter placement.
Blood was withdrawn from the vena cava to measure human recombinant relaxin plasma levels (Human Relaxin-2 Quantikine ELISA kit DRL200; R&D Systems, Minneapolis, MN). In all experiments, we used perfusate and bath solutions containing 30 ng/ml of the trial medication supplied.
Pressure-perfusion myograph. The flow-mediated vasodilation, the myogenic reactivity to pressure, and the compliance were analyzed in a pressure-perfusion myograph (Pressure Myograph System-Model P100; J. P. Trading, Aarhus, Denmark). The responses were determined in basic PBS (in mM: 119 NaCl, 4.69 KCl, 25 NaHCO 3, 1.17 MgSO4, 1.18 KH2PO4, 5.5 glucose, and 10 HEPES), with additional 2 mM EGTA and 0.01 mM sodium nitroprusside (for calcium-free PBS) to measure compliance and 2.5 mM CaCl2, 0.027 mM Na2EDTA (for calcium-PBS) to assess flow-mediated vasodilation and myogenic reactivity. The buffers were oxygenated with 95% O2 and 5% CO2 at a temperature of 37°C. Second-order mesenteric arteries (150 -400 m) were mounted on two opposing glass canules (125 m). Vascular inner diameter was measured through video recording (Vessel View; J. P. Trading). Arteries were equilibrated at an intraluminal pressure of 60 mmHg during 20 min. Subsequently, thromboxane A 2 agonist U-46619 (9,11-dideoxy-11␣,9␣-epoxymethanoprostaglandin F2␣; Sigma-Aldrich Chemie) was added (bath concentration of 10 Ϫ7 to 10 Ϫ6 M) to preconstrict vessels to 30 -40% of their basal diameter.
I. Flow-mediated vasodilation. Flow-mediated vasodilation is defined as the vasodilator response to a certain flow increase. After reaching a stable contraction, the flow in the vessel was increased every 2 min in 16.7 l/min steps from 0 up to 100 l/min (comparable to shear stress range of 0 -10 dyne/cm 2 ) in absence and presence of 100 M of the NO antagonist N G -nitro-L-arginine methyl ester (L-NAME; Sigma-Aldrich Chemie), while maintaining a mean intraluminal pressure of 60 mmHg. Vessels attaining Ͻ20% preconstriction, Ͻ10% vasodilation over the completed flow range, or with instable pressure resulting from fluid leakage were excluded from the study. Flow-mediated vasodilation was expressed as a percentage of the preconstriction status.
II. Myogenic reactivity and vascular compliance. Myogenic reactivity is defined as the vasoconstrictor response to a certain pressure increase in the presence of calcium. Compliance is defined as the vasodilator response to a certain pressure increase in the absence of calcium, to avoid smooth muscle cell contraction. A new mesenteric vessel was isolated and prepared as described above. Intraluminal pressure was increased every 2 min in 10-mmHg steps from 20 mmHg up to 110 mmHg to determine successive myogenic reactivity (measuring inner vessel diameter) and compliance [measuring outer/inner vessel diameter and vessel wall thickness and the stress-strain relationship (11)].
Wire myograph (response to phenylephrine). We studied the vasoconstrictor response to phenylephrine (Sigma-Aldrich Chemie) with a Mulvany Halpern myograph (Dual Wire Myograph-Model 400A; J. P. Trading). The bath was filled with physiological salt solution (in mM: 119 NaCl, 4.69 KCl, 2.5 CaCl 2, 25 NaHCO3, 1.17 MgSO4, 1.18 KH2PO4, 5.5 glucose, and 0.027 EDTA) and oxygenated with 95% O2 and 5% CO2 at a temperature of 37°C. Four second-order mesenteric arteries (150 -400 M) were mounted in two wire myographs, stabilized as previously described (24), and set at a tension equivalent generated at 90% of the inner circumference of 100 mmHg. The response to 124 mM KCl was measured (used for normalization of the phenylephrine response). The response to phenylephrine was determined in eight steps over a range from 10 Ϫ7 to 10 Ϫ5 M, in the absence or presence of 100 M L-NAME. The data of the two arteries in each myograph were averaged when available.
IPRK model. The intrinsic adaptation to relaxin of the kidney was assessed in the IPRK. Within the time frame of our protocol, this model is known to present stable renal function (22) , although one has to be restrictive to comparison of absolute values observed in vivo. Briefly, the right renal artery was cannulated via the left renal artery and aorta. The right ureter was cannulated for urine collection. Perfusion was started in situ, and the kidney was removed and placed in a perfused bath at a temperature of 37°C. The kidney was perfused at constant pressure of 90 mmHg with oxygenated cell-free KrebsRinger-Henselheit [containing (in mM) 113 NaCl, 4. Stabilization of the RPFF was accomplished during a 40-min period. From 40 to 60 min, the basal renal plasma flow (RPFF baseline) was determined. At 60 min, L-NAME was added at a final concentration of 100 M to the perfusate to investigate the contribution of NO to the relaxin (or placebo)-evoked vasodilator response up to 160 min (RPFF 160). RPFF was normalized for body weight (ml·min Ϫ1 ·100 g body wt Ϫ1 ). Relaxin family peptide 1 gene expression. The Rxfp1 gene expression was analyzed by quantitative polymerase chain reaction, according to the procedure described by Vodstrcil et al. (34) . Total RNA was extracted from frozen mesenteric arteries with Trizol (GIBCO-BRL) according to the manufacturer's instructions. Forward/reverse primers and 6-carboxy fluorescein-labeled TaqMan probes specific for the full-length rat Rxfp1 were from Biosearch Technologies (Novato, CA).
Statistical analysis. The data were expressed as means Ϯ SE; n indicates the no. of animals. Flow-mediated vasodilation and the responses to phenylephrine and RPFF were analyzed by nonlinear regression curve fitting (GraphPad Prism 4.0; Institute for Scientific Information, San Diego, CA). Subsequent curve fit estimates were as follows: maximal vascular diameter after flow change (Diam max), flow rate inducing 50% dilation, flow sensitivity (Flow50%), maximum response to phenylephrine (Rmax), and phenylephrine concentration inducing a 50% response (C50%), basal RPFF (RPFFbaseline), and RPFFbaseline minus RPFF160 (RPFFdelta). Overall myogenic reactivity (MRoverall; using the inner vessel diameter corrected for percentage preconstriction) and overall vascular compliance (VCoverall; using the inner vessel diameter) were analyzed by using ANOVA for repeated measures (Greenhouse-Geisser correction; SPSS 16.0.2; SPSS, Chicago, IL). Selective straight line curve fitting was performed for both myogenic reactivity (MR Ͼ60) and compliance (VCϾ60) of the inner vessel diameter, estimating the hill slope over the range of 60 -110 mmHg. Baseline characteristics were analyzed by using Students' t-test. In all analyses, we compared relaxin vs. placebo in young rats, relaxin vs. placebo in aged rats, and young vs. aged in placebo-treated rats. Rxpf1 gene expression was presented as normalized ⌬C T, transformed by 2 n where n ϭ (Ϫ⌬CT) (34) . A P value Ͻ0.05 was considered to be statistically significant.
RESULTS
The study population contained 20 young and 20 aged female virgin Wistar Hannover rats (mean age, respectively, 83 Ϯ 1 and 309 Ϯ 3 days). Aged rats weighed 29% more than young rats (208 Ϯ 2 vs. 268 Ϯ 5 g, P Ͻ 0.01). Plasma concentrations of human relaxin after infusion were comparable (74 Ϯ 16 vs. 94 Ϯ 8 ng/ml, P ϭ 0.30, in young and aged rats, respectively). At baseline, aged rats showed larger vessel diameters than observed in young rats (reaching statistical difference in two experimental settings: myogenic reactivity and response to phenylephrine) with a comparable percentage preconstriction (Table 1 ). Basal diameter, percentage preconstriction, and response to 124 mM KCl of mesenteric vessels were comparable for relaxin vs. placebo and for the presence vs. absence of L-NAME for each experimental setting (Table 1) .
Flow-mediated vasodilation. In young rats, relaxin enhanced flow sensitivity (decreased Flow 50% ) 2.67-fold (from 48 Ϯ 9 to 18 Ϯ 4 l/min, P ϭ 0.001) without changing maximal reactivity (Diam max 26 Ϯ 2 and 31 Ϯ 5% in relaxin-and placebotreated rats, respectively; Figs. 1 and 2 ). L-NAME blunted the relaxin effect on flow sensitivity (Flow 50% 30 Ϯ 10 and 28 Ϯ 6 l/min in relaxin-and placebo-treated rats, respectively). In aged rats, relaxin did not change flow sensitivity nor maximal reactivity (Flow 50% 50 Ϯ 10 and 40 Ϯ 9 l/min and Diam max 34 Ϯ 6 and 23 Ϯ 4% in relaxin-and placebo-treated rats, respectively), independent of NO blockade (Flow 50% 47 Ϯ 8 and 56 Ϯ 3 l/min in relaxin-and placebo-treated rats, respectively). Aging itself only decreased flow sensitivity 2.00-fold (from 28 Ϯ 6 to 56 Ϯ 3 l/min, P ϭ 0.001) when NO production is blocked.
Myogenic reactivity and vascular compliance. In young rats, chronic relaxin infusion reduced MR overall and MR Ͼ60 (from Ϫ1 Ϯ 2 to 7 Ϯ 3 m/10 mmHg) but did not change MR overall and MR Ͼ60 (from Ϫ1 Ϯ 4 to Ϫ1 Ϯ 2 m/10 mmHg) in aged rats (Fig. 3) . Aging itself did not alter MR overall and MR Ͼ60 (from Ϫ1 Ϯ 2 to Ϫ1 Ϯ 4 m/10 mmHg) compared with young placebo-treated rats.
In young and aged rats (Fig. 4) , relaxin exposure did not affect stress-strain curves, VC overall , and VC Ͼ60 (young: from 3 Ϯ 1 to 3 Ϯ 2 m/10 mmHg; aged: from 4 Ϯ 2 to 3 Ϯ 3 m/10 mmHg). Aging itself increased VC overall (P Ͻ 0.01) without affecting VC Ͼ60 (from 3 Ϯ 1 to 4 Ϯ 2 m/10 mmHg) compared with young placebo-treated rats. However, this is rather dependent upon enlarged basal diameter than changes in vessel elasticity, since both curves run parallel, and the stressstrain relationship was comparable.
Response to phenylephrine. In young rats, relaxin reduced the sensitivity to phenylephrine (C 50% ) by 28% (P ϭ 0.01; Table 2 ), an effect partially persistent after NO blockade (19%, P ϭ 0.03). Relaxin did not affect the R max to phenylephrine. In aged rats, relaxin neither affected C 50% nor R max , whereas under NO blockade relaxin decreased C 50% by 67% (P ϭ 0.05). Aging itself did not alter either sensitivity or the maximum response to phenylephrine, although aging reduced the maximum response under L-NAME (P ϭ 0.05).
IPRK model. In the kidney (Fig. 5) , in both young and aged rats, relaxin did not affect RPFF baseline (young: 6.7 Ϯ 0.1 and 6.9 Ϯ 0.2 ml·min Ϫ1 ·100 g Ϫ1 ; aged: 6.0 Ϯ 0.1 and 5.7 Ϯ 0.1 ml·min Ϫ1 ·100 g Ϫ1 in relaxin-and placebo-treated rats, respectively), nor did it change the contribution of NO to the vascular tone, measured in RPFF delta (young: 4.1 Ϯ 0.3 and 3.9 Ϯ 0.4 ml·min Ϫ1 ·100 g Ϫ1 ; aged: 4.3 Ϯ 0.2 and 4.1 Ϯ 0.2 ml·min Ϫ1 ·100 g Ϫ1 in relaxin-and placebo-treated rats, respectively). Aging reduced RPFF baseline by 17% (from 6.9 Ϯ 0.2 to 5.7 Ϯ 0.1 ml·min Ϫ1 ·100 g Ϫ1 , P ϭ 0.001) without affecting NO-mediated vasodilation (RPFF delta : 6.7 Ϯ 0.1 and 6.0 Ϯ 0.1 ml·min Ϫ1 ·100 g Ϫ1 ), when comparing young vs. aged placebotreated rats.
Rxfp1 gene expression. Rxfp1 was expressed in the mesenteric arteries. However, there was no significant difference in expression between the young and aged rats treated with relaxin or placebo (Fig. 6) . 
DISCUSSION
The present study reveals three important observations. Relaxin promotes mesenteric flow-mediated vasodilatation by stimulating the NO pathway and reduces myogenic tone and responsiveness to phenylephrine. Interestingly, moderate aging appears to attenuate all of these relaxin-mediated effects.
Finally, relaxin does not affect ex vivo RPFF in either young or aged rats.
Our data on functional responses in mesenteric arteries of young rats are mostly in line with observations made by others. Relaxin enhances flow-mediated vasodilation by increasing NO production at lower flow rates and decreases myogenic reactivity (21, 26) . The increased NO production seems to be a direct effect of relaxin, since relaxin exposure to isolated cells directly stimulates NO synthesis (17) . Relaxin NO-dependently reduces sensitivity to angiotensin II (9), which is in line with our phenylephrine data. We did not detect any influence of relaxin on vascular compliance, although one study suggests that relaxin decreases compliance (21) . This discordance may be the result of a variety of differences in protocol, as Li et al. (21) used Long Evans rats, supplies porcine relaxin at a rate of 4 g/h for 3 days, and sets the pressure range of interest at 20 -60 mmHg. Considering the extent of all changes, relaxin enhances the vasodilator state by affecting different local vascular responses, mainly by upregulation of NO-mediated vasodilation.
Vascular effects of aging in female rodents is still a topic of debate, since some observed reduced NO-dependent flowmediated vasodilation (1) and myogenic reactivity (19) , and increased phenylephrine reactivity (13), while others did not detect any age-dependent effects on these parameters (31) . We were also unable to observe an age-induced effect on NOdependent vasodilation, myogenic reactivity, or sensitivity to phenylephrine. Additionally, aging enhances vascular compliance (19) . In line with morphological data (33) , this is mainly due to increased basal vessel diameter rather than changes in vessel elasticity, considering the shape of the curve (Fig. 4) . As far as we know, this is the first study addressing effects of relaxin on mesenteric vascular function in relation to aging. We observed that, at the onset of reproductive senescence, basal responses of mesenteric arteries are comparable to those observed in young rats, implying normal endothelial function in the moderately aged rat. However, all relaxin-induced mesenteric vasodilator responses, mostly NO-dependent, are blunted. These findings suggest that, despite normal endothelial function, the endothelium in aged subjects suffers from endothelial-dependent resistance to relaxin.
Relaxin is known to increase in vivo renal plasma flow up to 40% by stimulating the NO pathway (9) and to reduce myo- Values presented as means Ϯ SE; n, no. of animals. Experiments were performed in the wire myograph in the absence and presence of 100 M L-NAME. Curve-fit estimates are as follows: concentration of phenylephrine inducing a 50% response (C50%), maximum response (Rmax) as a percentage of the maximum response to 124 mM KCl. §P Ͻ 0.05 between placebo-and relaxin-pretreated rats. #P Ͻ 0.05 between young and aged rats. genic reactivity in isolated renal arteries (26) . In aged rats, the increase in renal plasma flow is even more pronounced (11) . We observed that, in isolated kidney, relaxin did not affect RPFF in either young or aged rats. One may allege that renal plasma flow and RPFF are not the same parameters, although likely to be strongly related, and that perfusate viscosity and solutions' oxygen delivery capacity are important factors jeopardizing whole organ perfusion function. In our model, the oxygen carrier Pluronic was added to the perfusate to optimize both factors. In the presence of this supplement, we were able to detect a subtle aging-induced reduction in RPFF without concomitant changes in NO availability, as observed in in vivo studies (11) , possibly as a consequence of age-related loss in the number of functional glomeruli (3). We therefore think that merits of the model are unlikely to explain the absence of response to relaxin. Our findings indicate that, in the presence of both myogenic and junxtaglomerular control, the isolated kidney is insensitive to relaxin in both young and aged subjects and that extrarenal factors mediate relaxin-dependent renal vasodilation.
There are some limitations to our study design. First, our human relaxin plasma levels were a little higher than 30 ng/ml, as reported by others (9) . This may be explained by differences in volume distribution or relaxin metabolism and clearance among different rat strains. Second, literature reports different physiological levels of relaxin among humans and rats (1 and 30 ng/ml, respectively) (28) . It is difficult to interpret these differences and make comparison to our study, since there is no international standardization in the various relaxin assays used. Third, the female rats were not selected for a particular stage of their estrous cycle. This may have affected our results, since high levels of estrogen could affect vascular tone. However, our randomization procedure was designed to distribute the estrous stages equally among groups, and this is unlikely to account for the observed effects of relaxin.
It is thought that the vascular effects of relaxin are mediated through activation of the G protein-coupled relaxin family peptide receptor (RXFP1), initiating both an inferior vasoconstrictor and a predominant vasodilator pathway. Activation of the mitogen-activated protein kinase pathway induces vasoconstriction (36) , where stimulation of the nitric oxide synthasemediated phosphatidylinositol 3-kinase (PI 3 K) pathway enhances vasodilation (15) . Moreover, matrix metalloprotease-2 is also involved (7) . The influence of relaxin on the vascular tone is likely a combined result of these pathways. It is unlikely that aging attenuates vascular Rxfp1 expression because we did not detect any differences between young and aged rats. Because aging is associated with downregulation of the vasodilatory PI 3 K pathway at the Akt/protein kinase B level (27, 30) , this implies that aging affects the downstream pathway. This may explain the aging-induced relaxin resistance, since relaxin equally activates both the vasodilator and vasoconstrictor pathway. Whether higher concentrations of relaxin may be capable of overcoming the attenuated response, seen at a lower dose, remains to be elucidated. Nevertheless, one may speculate that resistance to relaxin relates aging-associated circulatory maladaptation with gestational hypertensive disease.
In summary, aging abolishes the physiological vasodilator response to relaxin, without affecting baseline vascular function. The disability to develop a pronounced relaxin-induced vasodilator state supports our concept of relaxin resistance in aged subjects.
